A treat-to-target strategy in which TNF inhibitors are tapered is non-inferior to a regimen without tapering for maintaining low disease activity in patients with psoriatic arthritis or axial spondyloarthritis, according to data.
“TNF inhibitors still carry some disadvantages, such as higher patient burden — injections — higher infection rate and costs,” Celia Michielsens, MD, of the rheumatology department at Sint Maartenskliniek, in the Netherlands, told Healio. “A way to alleviate these disadvantages would be the introduction of treat-to-target tapering